Serum soluble CD8 concentration is an indicator of disease activity in patients with Graves' disease

C. Balázs, A. Bokk, N. R. Farid

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Cell-mediated immunity is important in the pathogenesis of Graves' disease. Activation of T cells is apparently associated with the release of soluble CD8 (sCD8) and CD4 (sCD4) molecules from the corresponding T cell subset. To test the possibility that the concentrations of these molecules may be related to Graves' disease activity, we measured serum sCD8 and sCD4 concentration in 58 Graves' patients using ELISA technique before and after treatment with methimazole as well as in 10 patients with toxic nodular goiter. sCD8 was significantly elevated in thyrotoxic patients [609.9 ± 118 (SD) U/ml] compared to controls (264.1 ± 98.8, p <0.001) and normalized when patients became euthyroid as a result of methimazole treatment (278.7 ± 89.1). The mean sCD8 concentration in the patients with toxic nodular goiter was 302 ± 28 U/ml, no different from control. The sCD4 level in the Graves' disease group was not different from control values and did not change significantly with treatment. Correlations were found between the levels of serum thyroid hormone(s) and sCD8 concentration but not with anti-TSH receptor antibodies in the 50 patients with Graves' disease. In addition, serum sCD8 studied prospectively in eight patients after discontinuation of methimazole, increased before the rise in serum T4, and well before the clinical relapse of thyrotoxicosis. It is concluded that sCD8 is a useful marker for the activation of CD8+ cells in Graves' disease.

Original languageEnglish
Pages (from-to)27-30
Number of pages4
JournalThyroid
Volume4
Issue number1
Publication statusPublished - 1994

Fingerprint

Graves Disease
Methimazole
Serum
Nodular Goiter
Poisons
CD4 Antigens
Thyrotoxicosis
T-Lymphocyte Subsets
Thyroid Hormones
Cellular Immunity
Therapeutics
Enzyme-Linked Immunosorbent Assay
T-Lymphocytes
Recurrence

ASJC Scopus subject areas

  • Endocrinology

Cite this

Serum soluble CD8 concentration is an indicator of disease activity in patients with Graves' disease. / Balázs, C.; Bokk, A.; Farid, N. R.

In: Thyroid, Vol. 4, No. 1, 1994, p. 27-30.

Research output: Contribution to journalArticle

@article{718e6b65dcdb43f9a0a87dc1d6f77bbc,
title = "Serum soluble CD8 concentration is an indicator of disease activity in patients with Graves' disease",
abstract = "Cell-mediated immunity is important in the pathogenesis of Graves' disease. Activation of T cells is apparently associated with the release of soluble CD8 (sCD8) and CD4 (sCD4) molecules from the corresponding T cell subset. To test the possibility that the concentrations of these molecules may be related to Graves' disease activity, we measured serum sCD8 and sCD4 concentration in 58 Graves' patients using ELISA technique before and after treatment with methimazole as well as in 10 patients with toxic nodular goiter. sCD8 was significantly elevated in thyrotoxic patients [609.9 ± 118 (SD) U/ml] compared to controls (264.1 ± 98.8, p <0.001) and normalized when patients became euthyroid as a result of methimazole treatment (278.7 ± 89.1). The mean sCD8 concentration in the patients with toxic nodular goiter was 302 ± 28 U/ml, no different from control. The sCD4 level in the Graves' disease group was not different from control values and did not change significantly with treatment. Correlations were found between the levels of serum thyroid hormone(s) and sCD8 concentration but not with anti-TSH receptor antibodies in the 50 patients with Graves' disease. In addition, serum sCD8 studied prospectively in eight patients after discontinuation of methimazole, increased before the rise in serum T4, and well before the clinical relapse of thyrotoxicosis. It is concluded that sCD8 is a useful marker for the activation of CD8+ cells in Graves' disease.",
author = "C. Bal{\'a}zs and A. Bokk and Farid, {N. R.}",
year = "1994",
language = "English",
volume = "4",
pages = "27--30",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Serum soluble CD8 concentration is an indicator of disease activity in patients with Graves' disease

AU - Balázs, C.

AU - Bokk, A.

AU - Farid, N. R.

PY - 1994

Y1 - 1994

N2 - Cell-mediated immunity is important in the pathogenesis of Graves' disease. Activation of T cells is apparently associated with the release of soluble CD8 (sCD8) and CD4 (sCD4) molecules from the corresponding T cell subset. To test the possibility that the concentrations of these molecules may be related to Graves' disease activity, we measured serum sCD8 and sCD4 concentration in 58 Graves' patients using ELISA technique before and after treatment with methimazole as well as in 10 patients with toxic nodular goiter. sCD8 was significantly elevated in thyrotoxic patients [609.9 ± 118 (SD) U/ml] compared to controls (264.1 ± 98.8, p <0.001) and normalized when patients became euthyroid as a result of methimazole treatment (278.7 ± 89.1). The mean sCD8 concentration in the patients with toxic nodular goiter was 302 ± 28 U/ml, no different from control. The sCD4 level in the Graves' disease group was not different from control values and did not change significantly with treatment. Correlations were found between the levels of serum thyroid hormone(s) and sCD8 concentration but not with anti-TSH receptor antibodies in the 50 patients with Graves' disease. In addition, serum sCD8 studied prospectively in eight patients after discontinuation of methimazole, increased before the rise in serum T4, and well before the clinical relapse of thyrotoxicosis. It is concluded that sCD8 is a useful marker for the activation of CD8+ cells in Graves' disease.

AB - Cell-mediated immunity is important in the pathogenesis of Graves' disease. Activation of T cells is apparently associated with the release of soluble CD8 (sCD8) and CD4 (sCD4) molecules from the corresponding T cell subset. To test the possibility that the concentrations of these molecules may be related to Graves' disease activity, we measured serum sCD8 and sCD4 concentration in 58 Graves' patients using ELISA technique before and after treatment with methimazole as well as in 10 patients with toxic nodular goiter. sCD8 was significantly elevated in thyrotoxic patients [609.9 ± 118 (SD) U/ml] compared to controls (264.1 ± 98.8, p <0.001) and normalized when patients became euthyroid as a result of methimazole treatment (278.7 ± 89.1). The mean sCD8 concentration in the patients with toxic nodular goiter was 302 ± 28 U/ml, no different from control. The sCD4 level in the Graves' disease group was not different from control values and did not change significantly with treatment. Correlations were found between the levels of serum thyroid hormone(s) and sCD8 concentration but not with anti-TSH receptor antibodies in the 50 patients with Graves' disease. In addition, serum sCD8 studied prospectively in eight patients after discontinuation of methimazole, increased before the rise in serum T4, and well before the clinical relapse of thyrotoxicosis. It is concluded that sCD8 is a useful marker for the activation of CD8+ cells in Graves' disease.

UR - http://www.scopus.com/inward/record.url?scp=0028210673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028210673&partnerID=8YFLogxK

M3 - Article

C2 - 8054859

AN - SCOPUS:0028210673

VL - 4

SP - 27

EP - 30

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 1

ER -